25 August 2017

Created in 2009, OJ-Bio has developed a Surface Acoustic Wave (SAW) biosensor platform. The development has reached a critical milestone and both partners have agreed that the time is right to transfer all activities to Japan for manufacturing.

During the transitional period following the agreed ending of the joint-venture in October 2016, OJ-Bio and its shareholders have been focused on a smooth and orderly transition while achieving their goals and upholding their commitments to their employees, customers and business partners.

Dr Hiromi Yatsuda and Hideo Kikuchi of JRC and Dr Dale Athey, CEO, Dr Roger Duggan, Director of Orla Protein Technologies, will focus on their roles within JRC and Orla respectively and resign their roles as board members of OJ-Bio Ltd.

JRC - Japan Radio Co. Ltd. published this content on 25 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 August 2017 02:02:05 UTC.

Original documenthttp://www.jrc.co.jp/eng/about/news/2017/0825-1.html

Public permalinkhttp://www.publicnow.com/view/731CA703657BAE43E441A971EE105523BC767BD7